ALAMEDA, Calif., Jan. 18, 2019 /PRNewswire/ -- Penumbra, Inc.
(NYSE: PEN) today announced that two new Board members were
appointed to its Board of Directors (the "Board") on January 17, 2019. Ms. Janet Leeds was appointed to the Board as a
Class I director, effective immediately, and Ms. Surbhi Sarna was appointed to the Board as a
Class II director, effective July 1,
2019. With the addition of these two directors, the Penumbra
Board will be comprised of eight directors, six of whom are
independent.
"We are thrilled to welcome Janet and Surbhi to our
Board. Both of these individuals will bring added experience,
perspective, and capability to our Board of Directors which will be
invaluable as we continue to grow and scale our company. Janet
brings to the Board a strong healthcare background with experience
in organizational development and governance. Surbhi brings
new capabilities that will complement the skills of our existing
Board and additional perspective to advise on topics that are
important to innovation and our future growth. The addition of
Janet and Surbhi will greatly benefit the Board and management team
at Penumbra, and I look forward to their help and counsel as we
continue our mission to positively impact many more patients and
families in the future," said Adam
Elsesser, Chairman, Chief Executive Officer and
President.
Ms. Leeds has held a number of leadership and consulting
roles in academic healthcare settings over more than thirty years.
Currently, Ms. Leeds serves as an Administrative Director at the
Seattle Cancer Care Alliance ("SCCA"), a cancer center comprising
Fred Hutchinson Cancer Research Center, Seattle Children's Hospital
and UW Medicine. From 2005 to 2009, Ms. Leeds served as the
Administrator for the Fred Hutchinson/University of Washington Cancer Consortium.
From 2000 to 2005, Ms. Leeds served as the Director of Planning at
the Fred Hutchinson Cancer Research Center. From 1996 to
2000, Ms. Leeds served in various positions that were instrumental
to the formation and development of the SCCA. Prior to that,
from 1987 to 1995, Ms. Leeds held management consultant positions
of increasing responsibility at ECG Management Consultants, where
she primarily consulted with academic medical centers. Ms.
Leeds received a BA from Stanford
University and an MBA from the University of Washington.
Ms. Sarna is the CEO and founder of nVision Medical, a
healthcare company developing pioneering technology to enable early
detection of ovarian cancer. Ms. Sarna founded nVision in
2011, with the intention of fulfilling an unmet clinical
need. She has led the company from its inception and through
its earliest days of product development, funding and initial
clinical trials. In April 2018,
nVision Medical was acquired by Boston Scientific. Ms. Sarna
now leads the efforts to commercialize the technology developed by
nVision Medical at Boston Scientific. Prior to her founding of
nVision, Ms. Sarna held a variety of roles in healthcare, including
roles at BioCardia and Abbott Vascular. Ms. Sarna received a
BA from the University of California,
Berkeley.
About Penumbra
Penumbra, Inc., headquartered
in Alameda, California, is a
global healthcare company focused on interventional therapies.
Penumbra designs, develops, manufactures and markets innovative
devices and has a broad portfolio of products that addresses
challenging medical conditions and significant clinical needs
across two major markets, neuro and peripheral vascular. Penumbra
sells its products to hospitals primarily through its direct sales
organization in the U.S., most of Europe, Canada and Australia, and through distributors in select
international markets. Penumbra and the Penumbra logo are
trademarks of Penumbra, Inc.
Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/penumbra-inc-appoints-janet-leeds-and-surbhi-sarna-to-its-board-of-directors-300781064.html
SOURCE Penumbra, Inc.